From early development through to commercial manufacturing in the CDMO industry.
STAND NR. 83
Our company began its journey back in 1995 with the management buyout of a solid dose facility in Stockholm, including a portfolio of around 20 well-known pharmaceutical products.
Over the years, Recipharm has continued to grow organically and through the acquisition of 30 + facilities to become the fourth largest global CDMO.
In March 2021, Recipharm AB was delisted from the stock exchange and became a private company owned by private equity firm EQT IX.
Today, Recipharm remains headquartered in Sweden and now includes around 30 manufacturing and development facilities in Europe, India, Israel and North America. The company is one of the oldest and most experienced CDMOs in the world and we are proud of what we have achieved.